Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult and teenage (\>/=16) male or female who will undergo surgery for multilevel (\>4 level) spinal fusion from a posterior approach with general anesthesia, and who are fluent English speakers such that they can complete the pain score and satisfaction questionnaires whose scores are a critical outcome variable.~* If female, subject is non-lactating and is either:~* Not of childbearing potential~* Of childbearing potential but is not pregnant at time of baseline as determined by pre-surgical pregnancy testing.~* Subject is ASA physical status 1, 2, or 3.~Exclusion Criteria:~* anxiety~* psychiatric disorder~* Allergy or sensitivity to ketamine or dilaudid~* Deemed un-acceptable by study team~* Cognitively impaired (by history)~* Subject requires chronic antipsychotic medication~* Subject known to be in liver failure~* Subject for whom opioids or ketamine are contraindicated~* Patients with narrow angle glaucoma~* Patients with a history of psychosis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine Naive (Type: ACTIVE_COMPARATOR): After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours.
- Naive Placebo (Type: PLACEBO_COMPARATOR): Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
- Tolerant Placebo (Type: PLACEBO_COMPARATOR): Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
- Tolerant Ketamine (Type: EXPERIMENTAL): After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).